MDT Stock Recent News

I happily own stock in Medtronic (MDT -2.25%), one of the largest medical device makers in the world. Of late, the company is struggling through a rough patch that has Wall Street worried about the future.

Medtronic delivered solid earnings, with standout growth in Cardiovascular, but overall performance remains mixed due to weaker Neuroscience and MedSurg segments. Elliott Management's activist involvement and new board appointments could drive operational improvements and strategic divestitures, echoing past success at Cardinal Health. Valuation is attractive on a PEG basis, but I remain on hold, awaiting clear evidence of sustainable earnings momentum and operational execution.

A clutch of post-earnings price target increases by analysts helped raise Medtronic's (MDT 3.59%) stock at a healthy rate on Wednesday. The sturdy medical device specialist's shares rose by almost 4% on the day as a consequence, a rate that looked especially good next to the S&P 500's (^GSPC -0.24%) 0.2% drop.

Medtronic (MDT -0.31%), a global medical technology leader specializing in cardiovascular, neuroscience, and surgical devices, reported Q1 FY2026 earnings on August 19, 2025. The most notable news from the release was a strong beat on both profits and revenue: Non-GAAP earnings per share reached $1.26, compared to estimates of $1.23, while Non-GAAP revenue hit $8.54 billion, $160 million above expectations. The company also raised its full-year FY26 non-GAAP EPS outlook, supported by solid revenue growth in its Cardiovascular and Diabetes segments. Overall, The quarter showed continued operational momentum, but also revealed ongoing margin pressures and a major portfolio move with the planned spin-off of the Diabetes business. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q4 2025 earnings report. Medtronic develops and manufactures a wide range of medical devices, including implantable cardiac pacemakers, heart val

Medtronic (NYSE:MDT) will report earnings on Tuesday, August 19, 2025. Over the last five years, the stock's next-day move following results has been highly unpredictable: it posted a positive one-day return in 50% of instances (median gain of 2.5%) and a negative one-day return in the other 50% (median loss of -3.8%).

Medtronic (NYSE:MDT), which is renowned for inventing the world's first battery-operated implantable pacemaker, has over time earned respect as a worldwide leader in medical technology and has created substantial value for its shareholders. Although the company's advancements have influenced contemporary healthcare, its stock presents a more cautious narrative today.

If you are looking to buy some dividend stocks right now, you'll want to get to know Realty Income (O 1.28%), PepsiCo (PEP 1.02%), and Medtronic (MDT -1.02%). All three are reliable dividend payers with historically high yields, which suggests they are on sale.

The science that backs healthcare breakthroughs is mind-bogglingly complex. If you don't specialize in the medical space, you should probably avoid small, research-driven healthcare stocks.

Publicly traded corporations are under no obligation to pay dividends. Among those that do, many are rather subpar in the exercise, particularly with how often they raise their payouts.

Dividend yield is a commonly used metric for finding dividend stocks to buy and hold. The dividend yield is the amount of a company's dividend as a percentage of its stock price.